CVKD Cadrenal Therapeutics Inc.
Price Chart
Executive Summary
Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced receipt of official FDA End-of-Phase 2 meeting minutes providing a clear path to a pivotal Phase 3 trial for CAD-1005 in HIT, with an NDA submission projected in 2029. Subsequent to quarter end, the company completed a $2.5 million financing to support near-term development activities.
Actionable Insight
The EPS beat and clear FDA regulatory path for CAD-1005 are positive catalysts. However, the company needs additional capital to fund the Phase 3 trial. Monitor for financing announcements and initiation of patient enrollment in the pivotal study.
Key Facts
- Q1 2026 EPS -$1.04 vs consensus -$1.57 (beat by 33.8%)
- Received official FDA EOP2 meeting minutes guiding Phase 3 registration trial for CAD-1005 in HIT
- Plan to advance directly to randomized, blinded, placebo-controlled Phase 3 study in ~120 patients
- Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005
- Cash and cash equivalents of $2.3M as of March 31, 2026, with subsequent $2.5M financing on April 1
- Net loss of $2.5M in Q1 2026 vs $3.8M in Q1 2025
Financial Impact
EPS surprise of +33.8% vs consensus; $2.5M net loss; cash position $2.3M
Risk Factors
- Requires significant additional capital to complete Phase 3 trial; current cash may be insufficient
- Phase 3 trial may fail to meet endpoints
- Competing therapies or changes in standard of care for HIT
- Risk of dilution from future equity offerings
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290023 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 7, 2026
4w ago
|
Press Release
| $6.02 $4.19 | ▼ −30.40% | ▼ −33.53% | $4.21 (−30.07%) |
|
Apr 30, 2026
5w ago
|
8-K
| $6.67 $5.00 | ▼ −25.04% | ▼ −30.01% | $4.21 (−36.88%) |
|
Apr 1, 2026
9w ago
|
424B5
| $4.90 $5.59 | ▼ −14.08% | ▼ −4.36% | $4.21 (+14.08%) |
|
Mar 31, 2026
10w ago
|
8-K
| $5.12 $5.79 | ▲ +13.09% | ▲ +3.66% | $4.21 (−17.77%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $5.12 $5.79 | ▲ +13.09% | ▲ +3.66% | $4.21 (−17.77%) |
|
Mar 12, 2026
12w ago
|
8-K
| $7.18 $4.76 | ▼ −33.70% | ▼ −35.68% | $4.21 (−41.36%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $7.18 $4.76 | ▼ −33.70% | ▼ −35.68% | $4.21 (−41.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access